Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.

July 28, 2013 at 2:52 pm

J Antimicrob Chemother. 2012 Jul;67(7):1607-15.

Cai Y, Chai D, Wang R, Liang B, Bai N.

Source

Department of Clinical Pharmacology, PLA General Hospital, Beijing 100853, People’s Republic of China.

Abstract

Colistin is the last resort for treatment of multidrug-resistant Acinetobacter baumannii. Unfortunately, resistance to colistin has been reported all over the world. The highest resistance rate was reported in Asia, followed by Europe. The heteroresistance rate of A. baumannii to colistin is generally higher than the resistance rate. The mechanism of resistance might be loss of lipopolysaccharide or/and the PmrAB two-component system. Pharmacokinetic/pharmacodynamic studies revealed that colistin monotherapy is unable to prevent resistance, and combination therapy might be the best antimicrobial strategy against colistin-resistant A. baumannii. Colistin/rifampicin and colistin/carbapenem are the most studied combinations that showed promising results in vitro, in vivo and in the clinic. New peptides showing good activity against colistin-resistant A. baumannii are also being investigated.

PDF

http://jac.oxfordjournals.org/content/67/7/1607.full.pdf+html

multidrug resistance, heteroresistance, combination therapy

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Metodos diagnosticos, Resistencia bacteriana, Sepsis.

Herpes Zoster Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens.


Calendar

July 2013
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  

Most Recent Posts


%d bloggers like this: